Toni Choueiri, the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), posted on LinkedIn.
“JUST IN (and finally…): Pembrolizumab hits OVERALL SURVIVAL in KYN-564 adjuvant study in Kidney Cancer!!!
The time has finally come… via Business Wire.”
Source: Toni Choueiri/LinkedIn